Αρχική World News Opinion: ‘Medical research charities are falling through the cracks of COVID-19 Government...

Opinion: ‘Medical research charities are falling through the cracks of COVID-19 Government support’

Michelle Mitchell is our chief executive officer.

A few short months ago, our ambitious plans for 2020 were in full swing.

More than 4,000 of our funded researchers were working together in labs and hospitals across the UK and our 600 shops were buzzing with activity at the heart of the high street. The build up to our big fundraising calendar – the calendar that millions of our supporters make so special – was about to shift into high gear.

Those few short months already seem like a lifetime ago.

Since the pandemic began in the UK, much of our life-saving research has been forced to pause as universities closed and hospitals switched their focus to COVID-19, and many of our fundraising activities have ground to a halt, such as making the difficult decision to cancel Race for Life this year. The devastating impact on people affected by cancer and those that support them has been well documented, and we keep doing everything we can to help them.

The impact of COVID-19 has been felt in every corner of society, and the impact it’s having on Cancer Research UK and our mission to beat cancer is serious, and it is still unfolding. One of the biggest challenges we face as an organisation right now is managing the fall in our income this year, and the likely ongoing impact of COVID-19 – and one place we have been looking to for support is the Government.

But it has become increasingly clear over the last few weeks that while the Government has provided funding to some charities, medical research charities like Cancer Research UK have so far been overlooked, falling through the gaps of many Government support packages.

Without specific and strategic Government support, the COVID-19 pandemic could have a deep and long-lasting effect on our work and that of other medical research charities, damaging a research infrastructure in the UK that has taken decades to build, and slowing down vital progress for patients.

COVID-19 has affected everything we do

With almost every way we fund our cancer research impacted by COVID-19, we expect to see a £150 million (around 30%) drop in fundraising income between now and March 2021, as we’ve written about before. And as the wider economic impact of COVID-19 is beginning to be felt by everyone, including our donors, the future landscape for many of our fundraising events remains uncertain.

As a result, we have had to take the difficult decision to cut our research funding by £44 million this year in the first instance, and we are considering further reductions in planned spending for coming years.

As the largest independent funder of cancer research globally, we are critically concerned about the impact of this, and how this will limit our ambition to improve cancer survival.

Medical research charities are slipping through the cracks of Government funding

The Government recently announced a £750 million Charity Support Package. While this was a lot less than the sector needed to make up for lost income – estimated to be around £4.3 billion – it was a positive and welcome show of support.

But, like lots of other charities, Cancer Research UK faced huge challenges in trying to access this funding, and now it looks almost certain that we won’t benefit from this support.

More than half of the Government package – £370 million – has been set aside for small community charities through the National Lottery Community Fund. As more detail has emerged on the rest of the money, it’s become increasingly clear that medical research charities like Cancer Research UK will not be included.

Again, though welcome, the £1.25 billion funding announcement for research businesses will not help organisations like ours.

What support have we received?

Outside of COVID-19 measures, we’ve been able to access some support for our shops and staff.

Around 60% of Cancer Research UK’s total workforce have now been furloughed under the Government’s Job Retention Scheme. This means the Government is helping us pay their salaries.

Government has removed business rates – the tax that is applied to our charity shops – for smaller outlets like ours this year. But because charities normally get help with business rates, this measure offers limited benefit.

We have also been looking to access another Government grant scheme that supports smaller high street shops like ours. But this is limited to about £700,000 across our whole network of charity shops, which works out as support for just 30 of our 600 outlets. To put that in context, we’ll have paid £4.5 million just in rent across our network of closed shops by the end of June when they begin to reopen.

All in all, the financial support we are receiving from the Government is limited, and pales into comparison to the knock-on impact on our fundraising efforts.

Together we will still beat cancer

Cancer doesn’t stop during the pandemic. One in two people will get cancer in their lifetime, and we’re doing everything in our power to continue our mission to beat the disease. But without further support, our life-saving cancer research will be set back for years to come.

We’ll continue to make the case to Government, but now more than ever we need our dedicated supporters and partners to help us in any way they can.

We want to continue working towards seeing 3 in 4 people survive their cancer by 2034. With your help we know we can do just that; with your help we can make a difference for the thousands of people with cancer right now and the millions of people to come.

COVID-19 has slowed us down, but we will never stop. Together we will still beat cancer.

Michelle Mitchell is Cancer Research UK’s chief executive officer

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His House

A young boy in England got quite the surprise when he was handed a check for a job well done! The boy’s mom, Laura-Nicole, shared...

SABCS 2021: New Research and Updates in Breast Cancer Treatment and Side Effects

The 2021 San Antonio Breast Cancer Symposium (SABCS) was held from December 7 to 10 in San Antonio, Texas, and online. In this podcast,...

Cancer Research UK publishes gender and ethnicity pay gap reports

As part of Cancer Research UK’s ongoing commitment to improving the diversity of the organisation, the charity has today published its gender pay gap...

Can mRNA Vaccines Help Treat Cancer?

January 20, 2022, by NCI Staff A technician working on mRNA vaccine production. Credit: Image used with permission from BioNTech The coronavirus pandemic has thrown a spotlight...

A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma

COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival (PFS) in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in...

Wawa Employee Saves Life Of Customer Who Stopped Breathing After A Seizure

When 19-year-old John Wallop arrived for his 16-hour shift behind the deli counter at Wawa in Millville, New Jersey, he thought it would just...